MEPOLIZUMAB

mepolizumab 100 mg/mL injection, 1 mL pen device

MEPOLIZUMAB (15508F)

mepolizumab 100 mg/mL injection, 1 mL pen device
15508F
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Uncontrolled chronic obstructive pulmonary disease (COPD)
Treatment phase: Continuing treatment

Restriction

Indication: Uncontrolled chronic obstructive pulmonary disease (COPD)
Treatment phase: Grandfather arrangements - Transitioning from non-PBS to PBS-subsidised supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $1,605.34 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala